Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Ozark Integrated Circuits of Fayetteville has received two grants from NASA to develop heat-resistant circuits that can operate on the surface of Venus and AEDC board approval to further develop its patent-pending UV detector.
The Venture Center launched its Pitch 'N Pint series of startup pitch contests at the Flying Saucer in Little Rock's River Market District.
Before founding EquityNet in 2005, Judd Hollas was division manager for Beta-Rubicon Inc. of Fayetteville, a consulting firm specializing in technology assessment and business due diligence services. He has 20 years of experience as an independent technology analyst and investment manager in the private and public domains.
What can the rest of us businesspeople learn from the success Amazon had selling so much stuff in one day? I believe Amazon’s leadership made at least three good decisions when creating and planning its first Prime Day.